MSD India launches 9-valent Human Papillomavirus (HPV) vaccine, GARDASIL 9
India’s first gender-neutral HPV vaccine to help reduce HPV -related disease burden in Indian girls, women and boys
India’s first gender-neutral HPV vaccine to help reduce HPV -related disease burden in Indian girls, women and boys
Prostate cancer is the second-most common cancer in men and despite an increase in the number of available treatments for men with mCRPC, five-year survival remains low
One of the key factors driving the market growth is the rise in the occurrence of chronic cardiovascular diseases such as heart failure and coronary artery disease: Valuates Reports
As part of this strategic partnership, LTI with its digital, technical and life sciences domain capabilities, will help accelerate joint go-to-market pursuits and faster deployment for Clinpal Adopters
Chericof 12, the first prescription cough syrup in India which gives relief for up to 12 hours, is manufactured using Polistirex technology for sustained release of the drug
The CAC solution cleared by the U.S. FDA analyses already existing non-gated CT scans and quantifies the coronary artery calcium in order to identify, stratify, and facilitate treatment pathways for patients with cardiovascular disease
It is the first orally administered therapy for the treatment of two types of ANCA-associated vasculitis approved in Japan
Its DirectDetect reagent eliminates RNA extraction for rapid deployment of Covid-19 tests in affected countries
The investment will increase SpeeDx internal capacity to scale up manufacturing
In terms of volume, the company commands a market share 25 per cent globally for Gliclazide, as per the IQVIA report
Subscribe To Our Newsletter & Stay Updated